Skip to content

US · RNA · BIOTECHNOLOGY

Atrium Therapeutics, Inc. (RNA) intrinsic value and stock valuation

$6.92as of 2026-11-21 · Mkt cap 200.82M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Atrium Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values RNA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from RNA’s statements →

Atrium Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology San Diego, CA 92121 atriumtherapeutics.com

How the business is doing

Fiscal 2025–2025, USD

Revenue
$18.6M
20252025
Net income
-$-76.68M
20252025
Free cash flow
-$-42.57M
20252025
Total equity
$207.3M
20252025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2025–2025, USD
2025
Revenue$18.6M
Operating income-$-76.81M
Net income-$-76.68M
EPSd-$-4.48M
Operating cash flow-$-41.13M
Capital expenditure-$-1.45M
Free cash flow-$-42.57M
Total assets$278.4M
Total debt$3.67M
Net debt-$-266.33M
Total equity$207.3M
Cash and short-term investments$270M
Income statement
2025
Revenue$18.6M
Cost of revenue$0.00
Gross profit$18.6M
Research and development expenses$53.8M
Selling, general and administrative expenses$41.7M
Other expenses$0.00
Operating expenses$95.4M
Cost and expenses$95.4M
Interest income$0.00
Interest expense$0.00
Depreciation and amortization$320K
Ebitda-$-76.5M
Operating income-$-76.81M
Total other income/expenses, net-$-10K
Income before tax-$-76.83M
Income tax expense-$-140K
Net income-$-76.68M
Weighted average shares outstanding$17.1M
Weighted average diluted shares outstanding$17.1M
Balance sheet
2025
Cash and short-term investments$270M
Net receivables$0.00
Inventory$0.00
Total current assets$272.9M
Property, plant and equipment, net$5.51M
Goodwill and intangible assets$0.00
Long-term investments$0.00
Total non-current assets$5.51M
Total assets$278.4M
Accounts payable$4.4M
Short-term debt$3.67M
Deferred revenue$21.6M
Total current liabilities$41.8M
Long-term debt$0.00
Deferred revenue, non-current$28.7M
Total non-current liabilities$29.3M
Capital lease obligations$3.67M
Total liabilities$71.1M
Common stock$20K
Retained earnings$0.00
Accumulated other comprehensive income (loss)$0.00
Total equity$207.3M
Total investments$0.00
Total debt$3.67M
Net debt-$-266.33M
Cash flow statement
2025
Net income-$-49.5M
Depreciation and amortization$320K
Stock-based compensation$7.68M
Change in working capital-$-200K
Accounts receivable$0.00
Inventory$0.00
Accounts payable$3.73M
Net cash provided by operating activities-$-41.13M
Investments in property, plant and equipment-$-1.45M
Acquisitions, net$0.00
Net cash used for investing activities-$-1.45M
Common stock issued$0.00
Common stock repurchased$0.00
Dividends paid$0.00
Net cash used for financing activities$42.6M
Net change in cash$0.00
Cash at end of period$0.00
Operating cash flow-$-41.13M
Capital expenditure-$-1.45M
Free cash flow-$-42.57M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Atrium Therapeutics, Inc.

        Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.

        CEO
        Kathleen Gallagher
        Employees
        511
        Beta
        0.37

        Explore

        Frequently asked questions

        What is the intrinsic value of Atrium Therapeutics, Inc. (RNA)?

        InvestorsCraft does not currently publish an intrinsic value for RNA. How the IC value is calculated.

        Is RNA undervalued?

        InvestorsCraft does not publish an undervaluation signal for RNA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.